Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular Lymphoma
Verified date | April 2024 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I trial studies the side effects and best dose of duvelisib when given together with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib and nivolumab may work better in treating patients with Richter syndrome or transformed follicular lymphoma compared to giving duvelisib or nivolumab alone.
Status | Completed |
Enrollment | 7 |
Est. completion date | February 14, 2024 |
Est. primary completion date | February 14, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of CLL or small lymphocytic lymphoma (SLL) meeting International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria AND biopsy proven transformation to diffuse large B cell lymphoma (DLBCL), clinically consistent with Richter?s syndrome (RS) OR histologically diagnosed relapsed or refractory DLBCL including transformed follicular lymphoma (tFL) ineligible for or refractory to platinum containing salvage therapy for the dose escalation portion of the study. For the dose expansion phase only patients with CLL with transformation to DLBCL or tFL will be eligible - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Absolute neutrophil count (ANC) >= 500/uL - Platelet count >= 30,000/uL (unless due to bone marrow involvement) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN - Total bilirubin =< 1.5 ULN (unless due to liver involvement, hemolysis, or Gilbert?s disease) - Creatinine clearance >= 40 mL/min (Cockcroft-Gault estimated) - Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug - Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study - Patients must sign an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study Exclusion Criteria: - Documented infection with human immunodeficiency virus (HIV) or chronic, active hepatitis B or C infection - Any chemotherapy or monoclonal antibodies within 14 days or kinase inhibitors (except BTKi) within 5 half-lives before cycle 1, day 1 (C1D1). BTK inhibitors may be continued until 2 days prior to C1D1. Steroids are allowed for palliation of symptoms due to lymphoma - Toxicity from previous therapy which has not resolved to grade 1 (or patient?s previous baseline) - Other active malignancies except those treated with curative intent with no active disease at the time of study entry or those felt to be at low risk of progression or recurrence over the next 2 years (such as low risk prostate cancer on active surveillance) - New York Heart Association (NYHA) class III/IV heart disease or other significant medical condition or organ system dysfunction which could compromise the subject?s safety or put the study outcomes at undue risk - Uncontrolled systemic infection - Unable to swallow capsules or significant malabsorption syndrome, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction at the time of screening - Patients who are pregnant or breastfeeding - Patients with known central nervous system (CNS) involvement by CLL or lymphoma - Patients who have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to C1D1 or have active graft-versus-host disease are excluded |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
David Bond, MD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Response to duvelisib in combination with nivolumab | Will be correlated with cytogenetic/fluorescence in-situ hybridization abnormalities of the chronic lymphocytic leukemia (CLL) and lymphoma compartments (for patients with Richter syndrome). The chi-squared test and logistic regression will be utilized to evaluate the association. | Baseline | |
Other | Response to duvelisib in combination with nivolumab | Will be correlated with deoxyribonucleic acid (DNA) mutation of CLL and lymphoma and assessed in tumor samples and cell free DNA. The chi-squared test and logistic regression will be utilized to evaluate the association. | Baseline | |
Other | Changes in T, B, and NK cell number and function | Will be summarized using graphical method in a descriptive manner and tested using nonparametric Wilcoxon signed-rank test due to small sample size. | Up to 3 years | |
Primary | Maximum-tolerated dose (MTD) of duvelisib | The MTD is defined as the highest dose level where at most one patient out of six experiences dose-limiting toxicities. | Up to 28 days | |
Secondary | Overall response rate | Will be defined as the proportion of patients achieving a complete or partial response; any eligible patient who begins treatment with the combination regimen will be included in the denominator. Will be calculated with a 95% binomial confidence interval. | Up to 3 years | |
Secondary | Progression-free survival (PFS) | The method of Kaplan Meier will be used to estimate PFS. | From cycle 1, day 1 to date of progression or death, assessed up to 3 years | |
Secondary | Overall survival (OS) | The method of Kaplan Meier will be used to estimate OS. | From cycle 1, day 1 to date of progression or death, assessed up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|